GLP-1 Benefits & Risks: Biomarker Context for Better Decisions

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medications can be an effective tool for weight management and metabolic support, but whether they are right for you depends on your individual health status, medical history, and biological response patterns. Recent data shows approximately 50–70% of users experience clinically meaningful weight loss, though individual outcomes vary significantly based on multiple factors including genetic predisposition, underlying health conditions, and adherence to treatment protocols.

The question 'Is GLP-1 good for me?' cannot be answered with a simple yes or no. Instead, a comprehensive evaluation should consider your metabolic markers, family history, medication interactions, and how your body may respond based on genetic variations in key peptide pathways. PlexusDx supports this precision approach by pairing compounded GLP-1 options with optional genetic testing, enabling you and your provider to make data-informed decisions tailored to your specific biological context.

How GLP-1 Medications Work and What the Evidence Shows

GLP-1 receptor agonists mimic glucagon-like peptide-1, a natural hormone that regulates appetite, blood sugar, and gastric emptying. By binding to GLP-1 receptors in the brain and digestive system, these medications reduce hunger signals and promote satiety, supporting both weight loss and glycemic control in individuals with type 2 diabetes or obesity.

Clinical trials demonstrate that GLP-1 medications can reduce body weight by 5–22% depending on the specific drug, dosage, and individual factors. Beyond weight loss, studies show improvements in cardiovascular outcomes, blood pressure, and inflammatory markers in many users. However, benefits plateau without sustained lifestyle modifications including dietary consistency and regular physical activity.

Key Efficacy and Safety Considerations: A Clinical Overview

Evaluating whether GLP-1 is appropriate for you requires understanding both potential benefits and documented risks. This comparison framework highlights the clinical factors a qualified provider should assess during an initial consultation.

Clinical Factor	What You Should Know
Weight Loss Efficacy	Average 5–22% reduction depending on medication choice, dose, and individual response; effects require ongoing treatment
Cardiovascular Benefits	LEADER and SUSTAIN trials show reduced cardiovascular events in high-risk populations; benefits vary by individual risk profile
Gastrointestinal Side Effects	Nausea, vomiting, constipation, or diarrhea occur in 20–50% of users; typically mild-to-moderate and tend to diminish over weeks
Pancreatitis Risk	Rare but documented; caution advised in those with personal or family history of pancreatic disease or conditions
Thyroid Considerations	Black box warning for medullary thyroid carcinoma in rodent studies; avoid if personal/family history of thyroid cancer
Dehydration and Kidney Function	GLP-1 use may reduce fluid intake; monitoring renal function is essential, especially for those with baseline kidney disease
Cost and Access	Branded options are expensive; compounded alternatives from 503A pharmacies offer cost-effective access starting at $179–$309/month

Who Should Consider GLP-1 and Who Should Avoid It

GLP-1 medications may be appropriate for adults with a BMI greater than 27 with weight-related conditions, or BMI greater than 30, or those with type 2 diabetes seeking improved glycemic control. Candidates typically have realistic expectations, commitment to lifestyle changes, and absence of contraindications such as personal history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe gastrointestinal motility disorders.

Those with a history of pancreatitis, gallbladder disease, severe kidney or liver impairment, uncontrolled psychiatric conditions, or planned pregnancy should avoid GLP-1 treatment or discuss carefully with their provider. Additionally, individuals taking medications that interact with GLP-1 absorption or those unable to afford ongoing treatment should explore alternative approaches. A comprehensive medical evaluation is essential before starting any GLP-1 regimen.

Understanding Individual Variation: Why Genetics and Biomarkers Matter

Not all individuals respond identically to GLP-1 medications. Genetic variations in GLP-1 receptor signaling, appetite regulation genes, and metabolic pathways can influence both efficacy and side effect tolerance. For example, variations in the GLP1R and GIPR genes may modulate receptor sensitivity, while FTO and MC4R variants can affect baseline metabolic rate and appetite set point, potentially shaping individual weight loss trajectories.

PlexusDx's Precision Peptide Genetic Test examines key variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) to provide context about your peptide pathway predispositions. Understanding these genetic factors may help you and your provider anticipate which GLP-1 approach—compounded semaglutide, tirzepatide, or a dual-peptide protocol—aligns best with your biological profile. This information should always be interpreted alongside clinical assessment and current health markers.

How PlexusDx Supports a More Personalized Approach

PlexusDx's approach emphasizes precision medicine: combining compounded GLP-1 medications with optional genetic testing to provide biomarker context that may help inform more personalized treatment conversations. The Precision Peptide Genetic Test reveals predispositions in peptide signaling pathways—such as GLP-1 receptor sensitivity and appetite regulation genes—that can support a more nuanced dialogue between you and your provider about which GLP-1 formulation or dosing strategy may align best with your individual biology.

The genetic test identifies variations in four key pathways: GLP-1 receptor (GLP1R rs6923761), glucose-dependent insulinotropic polypeptide receptor (GIPR rs1800437), fat mass and obesity-associated gene (FTO rs9939609), and melanocortin-4 receptor (MC4R rs17782313). These variants do not predict exact medication response or guarantee outcomes, but they may help contextualize why some individuals experience robust GLP-1 effects while others see more modest results, and why side effect profiles vary considerably between users.

When considering whether GLP-1 is good for you, integrating genetic predisposition data with biomarker assessment (fasting glucose, lipids, liver and kidney function, inflammatory markers) and a detailed medical history creates a more complete picture. This multi-factor evaluation can support more confident decision-making about whether to start GLP-1, which formulation to try first (compounded semaglutide from $179/month, tirzepatide from $229/month, or microdose protocol at $129/month), and how to monitor response and side effects over time.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at from $209/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.